Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump

The stock trading graph of Johnson & Johnson is seen on a smartphone screen.Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged.J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share. Here's what J&J reported for the fourth quarter compared with what Wall Street w ...